Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

This study has been terminated.
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc Identifier:
First received: December 3, 2002
Last updated: June 6, 2012
Last verified: June 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2004
  Estimated Primary Completion Date: No date given